Pharmacoeconomic Evaluation of Capecitabine in the Treatment of Digestive Malignant Tumor
- VernacularTitle:卡培他滨治疗消化道恶性肿瘤的药物经济学评价
- Author:
Xiaojia WANG
;
Zhanhong CHEN
;
Weiwu YE
;
Caijin LOU
- Publication Type:Journal Article
- Keywords:
Capecitabine;
Digestive malignant tumor;
Pharmacoeconomic evaluation
- From:
China Pharmacy
1991;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
0.05,X 2 =0.45),and the focus stability ratio were42.5%and32.4%respectively.Compared with the FOLFOX4group,the hospitalization course in capecitabine group is significantly shorter(8.5days vs25.3days,P=0.000)and the total medical cost was significantly lower(5941.7RMB vs13304.6RMB,P=0.001).The cost structure analysis showed that the direct and indirect medical costs of the FOLFOX4group increased more significantly(P=0.001)and the incidence for adverse effects of this group was lower than that of the capecitabine group.CONCLUSION:From the perspective of pharmacoeconomic evaluation,capecitabine is better than FOLFOX4in treating the digestive malignant tumor.
